Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins

Project description

Towards simpler and shorter treatments for malaria cure

Malaria is a disease spread to humans by certain types of mosquitoes. Even though it is preventable and curable, resistance to existing antimalarial medicines threatens recent progress in reducing illness and deaths, particularly in sub-Saharan Africa. The EU-funded CUREMAL project is developing and clinically evaluating GSK701, a novel antimalarial compound with a unique mechanism of action, as both monotherapy and in combination with pyronaridine. Clinical trials are being conducted in malaria-endemic countries and involve both adults and vulnerable populations, including children and adolescents. Alongside testing the treatment’s safety and effectiveness, the project aims to strengthen African research capacity and molecular surveillance of drug resistance, supporting the development of shorter and simpler malaria treatments.

Objective

CUREMAL project aims to address the urgent need for new malaria treatments due to the increasing resistance to current therapies. Malaria remains a significant global health challenge, particularly in sub-Saharan Africa, where it causes the majority of malaria-related deaths. The project focuses on developing GSK701, a novel antimalarial compound with a unique mechanism of action, showing no cross-resistance with existing drugs and potential for a single-dose cure.
The partners will conduct two clinical trials to evaluate the safety, efficacy, and pharmacokinetics of GSK701 in combination with pyronaridine. These trials will be carried out in malaria-endemic regions from Gabon, Tanzania, Uganda and Mozambique, targeting vulnerable populations, including children and adolescents. The trials will also involve detailed molecular surveillance to understand the effectiveness of the new treatment and monitor resistance patterns.
Key objectives include assessing the safety and tolerability of various dosing regimens, evaluating the pharmacokinetic/pharmacodynamic relationship, and identifying genetic variants associated with resistance. The project will also focus on building capacity in African research centres for conducting clinical trials and genetic surveillance. The expected outcomes include progressing GSK701 through development stages, enhancing molecular surveillance of antimalarial resistance, and fostering global and intra-African collaborations. The project aims to contribute to malaria control and elimination efforts, improve treatment adherence with simplified regimens, and support the achievement of the 2030 Sustainable Development Goals related to health.
By leveraging multidisciplinary expertise, cutting-edge technology and partners´ in-kind resources, CUREMAL seeks to make a significant impact on public health, providing a robust solution to the growing challenge of antimalarial resistance and advancing towards the ultimate goal of malaria eradication.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2025-01-two-stage

See all projects funded under this call

Coordinator

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
Net EU contribution
€ 0,00
Address
C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MAD
28760 TRES CANTOS MADRID
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 14 315 972,78

Participants (10)